Australia’s cannabis space has become an attractive area for investors since medical marijuana was legalized in 2016, but a new report warns that the market is still in its early stages.

In a co-authored industry note to investors sent out on Tuesday (November 12), Canaccord Genuity Australian equity analysts Cameron Bell and Matthijs Smith said it’s a case of “smoke without fire” when it comes to Australia’s current budding landscape for cannabis.


The update notes that the Australian market is struggling along with the global cannabis sector, causing a drop of about 40 percent in Canaccord’s Australian Cannabis Index over the past four months.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The struggle is being felt by cannabis markets across the world, including Canada and the US, as excitement about the space yields high expectations but is met with less-than-impressive results.

It isn’t all bad news for Australia, however. The analysts wrote that there have been marked improvements when it comes to growing patient numbers.

“Although we note the early stage of the sector in Australia and the associated volatility of a nascent industry, over the same period patient numbers domestically have continued to soar,” the note reads.

In October, the Therapeutics Goods Association (TGA), the regulator of medical cannabis in the country, approved 3,594 applications from patients seeking access to medical cannabis under Special Access Scheme-B, marking a 23 percent increase in approvals since September.

The TGA has now approved a total of 20,300 Special Access Scheme-B applications, and the two analysts said a majority of the approvals — 92 percent — have happened within the last year. That puts Australia on track to have 25,000 approvals by the end of 2019.

Medical cannabis continues to gain foothold in Australia

The swift rise in patient approvals could be driven by the state of New South Wales, which has loosened the requirements for prescribing medical marijuana, according to the Canaccord analyst pair. It has removed the need for state approval for medical cannabis applications in most cases.

New South Wales is joined by Western Australia, which on Tuesday announced will also make it easier for patients to get access to medical cannabis. Now general practitioners in the state can prescribe medical cannabis without having to refer to a specialist, unless the patient is under 16 years old or has a history of drug abuse.

In a statement, Western Australia Health Minister Roger Cook noted the benefits of offering a variety of options to patients.

“It is important for the Commonwealth to have a flexible system that expedites affordable access to new and emerging healthcare treatments,” said Cook.

The shift towards a more accessible system for medical cannabis across the country also follows the legalization of recreational cannabis in the Australian Capital Territory in September.

The new legislation, set to come into effect in January 2020, will allow people 18 years and older to possess up to 50 grams of dried flower and cultivate a maximum of four marijuana plants in their home.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

One major cannabis analyst gave her top stock pick this week as industry attention continues to converge on the path ahead for the US market.

Also this week, the CEO of Aphria (NASDAQ:APHA,TSX:APHA) gave an update on a critical merger and spoke about who holds the edge in the US in terms of American and Canadian cannabis operators.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its 2021 First Quarter Earnings Conference Call on Friday, May 7, 2021 at 8:30 a.m. EDT. Cronos Group’s senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

A live audio webcast of the earnings call will be available on the Company’s website at https://ir.thecronosgroup.com/events-presentations . The webcast of the call will be archived for replay on the Company’s website.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

A report just released in early April confirms that the cannabis beverage sector is thriving. According to this report from industry stalwart, Marijuana Business Daily while sales for vapes, pre-rolls and flower were lackluster, cannabis beverages shined:

Keep reading... Show less

BevCanna Enterprises (CSE:BEV,OTCQQ:BVNNF,FWB:7BC) CEO Marcello Leone shared how the company is scaling up its products to forge partnerships and explore opportunities across Canada, the US and Western Europe. 

“Getting your standard processing license and being fully compliant at a federal level is critical in Canada, and we were successful in getting that done. Now we’re getting ready to launch our Keef line of beverages within the next 45 days,” Leone said. 

As a young company, Leone said BevCanna has only started, but it took a four-pronged approach to make sure that it is a revenue-generating company prepared for the opening of many jurisdictions for CBD-based products.

“We are blessed that we have a beautiful infrastructure of our own, a state-of-the-art bottling facility with a capacity of almost 200 million bottles per annum and a strong balance sheet of $55 million. We are in a strong position to scale and grow this company.”

BevCanna has received a Standard Processing License from Health Canada and is now fully authorized to begin production at its full-service, high-capacity beverage manufacturing facility. The company will begin production of its white-label products, number one US cannabis beverage brand Keef and its in-house beverages through licensed Canadian retailers, positioning the company to fully capitalize on the burgeoning Canadian cannabis-infused beverage sector.

Watch the full interview with CEO Marcello Leone above.

Keep reading... Show less

BioHarvest Sciences (CSE: BHSC) will be presenting at the Benzinga Cleantech Small Cap Conference taking place on April 22, 2021. We invite our shareholders and all interested parties to explore cleantech small cap investment opportunities through two days of networking, dealmaking and discovery.

Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/clean-tech/

Keep reading... Show less